Recursion announces first patient dosed in Phase 12 clinical study of REC-1245, a potential first-in-class, RBM degrader for Biomarker-Enriched Solid Tumors and Lymphoma
| 031162CT5 | 90.13 5.02 5.28% |
About 62% of AMGEN's investor base is looking to short. The analysis of the overall prospects from investing in AMGEN INC suggests that many traders are, at the present time, alarmed. The current market sentiment, together with AMGEN's historical and current headlines, can help investors time the market. In addition, many technical investors use AMGEN INC bond news signals to limit their universe of possible portfolio assets.
AMGEN |
First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with 200 compounds synthesizedREC-1245 is a potent and selective RBM degrader with a potential first-in-class profile in Solid tumors and Lymphoma100,000 patients in the US and EU5 initially addressable SALT LAKE CITY, Dec. 03, 2024 -- Recursion , a leading clinical stage TechBio company deco
Read at finance.yahoo.com
 |
AMGEN Fundamental Analysis
We analyze AMGEN's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AMGEN using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AMGEN based on its fundamental data. In general, a quantitative approach, as applied to this corporate bond, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
AMGEN INC cannot be rated in Probability Of Bankruptcy category at this point.Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
AMGEN INC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with AMGEN bond to make a market-neutral strategy. Peer analysis of AMGEN could also be used in its relative valuation, which is a method of valuing AMGEN by comparing valuation metrics with similar companies.
Peers
AMGEN Related Equities
| 00108WAF7 | 00108WAF7 | 8.19 | ||||
| GOOG | Alphabet | 5.46 | ||||
| PYPL | PayPal Holdings | 2.24 | ||||
| RXRX | Recursion Pharmaceuticals | 1.47 | ||||
| INMD | InMode | 0.32 | ||||
| APLD | Applied Blockchain | 0.11 | ||||
| FUND | Sprott Focus | 0.49 | ||||
| 90331HPL1 | 90331HPL1 | 2.15 | ||||
| BBAI | BigBearai Holdings | 4.18 | ||||
| IONQ | IONQ | 9.52 |
Other Information on Investing in AMGEN Bond
AMGEN financial ratios help investors to determine whether AMGEN Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AMGEN with respect to the benefits of owning AMGEN security.